Case ReportCould Agomelatine Play a Role to Treat Anhedonia in Heroin Dependence?Preve, Matteo MD, PhDAuthor Information Sociopsychiatric Organization, Outpatient Psychiatric Service, Cantone Ticino, Switzerland The author declares no conflict of interest. Correspondence to: Matteo Preve, MD, PhD, Sociopsychiatric Organization, Via Agostino Maspoli 6, Mendriso 6850, Switzerland (e-mail: [email protected]). Addictive Disorders & Their Treatment: September 2021 - Volume 20 - Issue 3 - p 211-212 doi: 10.1097/ADT.0000000000000245 Buy Metrics Abstract Anhedonia is defined as a diminished ability to experience interest or pleasure, and is a critical psychopathologic dimension of major depressive disorder and is a commonly reported symptom among substance-dependent populations inside heroin addiction. The purpose of this report is to review the clinical evidence for the potential role of agomelatine to treat anhedonia in heroin dependence and literature review. We conducted a systematic review of the literature with the principal database (PubMed, Enbase, and PsychInfo) and we present a case report. Agomelatine was shown to be effective on anhedonia, depression, and anxiety in a subject with heroin dependence. The favorable effect of agomelatine on circadian rest-activity/sleep-wake cycle and on both depressive and anxiety symptoms is well knowed. To our knowledge in the literature there are no studies about the use of agomelatine to treat anhedonia in heroin addictated patient. We have any particular side effect and agomelatine was good tolerated. Further research is warranted to replicate our clinical and qualitative observations and, in general, quantitative studies in large samples followed up over time are needed. Methodological limitations, clinical implications, and suggestions for future research directions are considered. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.